RADIOLABELED MONOCLONAL ANTIBODY IMAGING OF TUMORS AND POSITRON EMISSION TOMOGRAP

这些研究旨在开发检测和治疗恶性肿瘤的改进方法。我们小组对经过国家癌症研究所不同实验室初步筛选后似乎有希望的抗体进行临床前评估，并开发这些抗体用于临床应用。评价其药代动力学和剂量学的临床试验由本课题组进行。一项与Waldmann博士(首席调查员)合作的放射免疫治疗试验正在进行中，在试验中我们使用了人源化的抗Tac单抗。在有结直肠癌病史且CEA升高但常规放射检查未发现疾病证据的患者中，比较99m抗CEA Fab(FDA批准)和F-18脱氧葡萄糖的影像研究仍在进行中。作为临床前评估的一部分，我们已经确定了一旦发生调制和内化，阿尔法标记抗体的命运。我们已经开始了初步研究，评估用于肿瘤治疗的抗体的预靶向性。

These studies are designed to develop improved methods for detect-ing and treating malignancies. Our group performs preclinical evaluation of antibodies that appear to be promising after initial screening by various laboratories at the National Cancer Institute and develops these antibodies for clinical application. The clinical trials evaluating their pharmacokinetics and dosimetry are performed by our group. A collaborative radioimmunotherapy trial with Dr. Waldmann (Principal Investigator) in which we used humanized anti-tac monoclonal antibody, is ongoing. Imaging studies comparing the use of Tc-99m anti- CEA Fab (FDA approved) and F-18 deoxyglucose in patients with previous history of colorectal carcinoma and rising CEA with-out evidence of disease by conventional radiographic modalities are ongoing. We have characterized the fate of alpha emitting labeled antibody once modulation and internalization occur, as part of their preclinical evaluation. We have begun preliminary studies evaluating pretargeting of antibodies for tumor therapy.